BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 19, 2016
View Archived Issues
Discovery of a potent and selective BCR-ABL inhibitor for chronic myeloid leukemia
Read More
Scientists steer ligand bias between beta-arrestin 2 and G protein pathway for biased CXCR3 agonists
Read More
Lead Discovery Center and Merck KGaA report proteasome inhibitors
Read More
Shanghai Haiyan Pharmaceutical Technology and Yangtze River Pharmaceutical disclose EGFR inhibitors
Read More
Domain Therapeutics patents metabotropic glutamate receptor modulators
Read More
Hutchison MediPharma announces PI3K inhibitors
Read More
FDA grants breakthrough therapy designation to Keytruda in classical Hodgkin's lymphoma
Read More
Merck & Co. patent describes IRAK-4 inhibitors
Read More
Update on the type 2 diabetes drug candidate TT-401
Read More
FDA approves Photrexa Viscous, Photrexa and KXL System to treat progressive keratoconus
Read More
Phase II GAMES results reported for RP-1127 for prevention of edema after ischemic stroke
Read More
NiCox submits NDA for AC-170 to treat ocular itching associated with allergic conjunctivitis
Read More
ImmunoBiochem and CCAB partner to develop antibody-drug conjugates for breast cancer
Read More
Milestone achieved in DR5 antibody collaboration between iDD biotech and Genmab
Read More
NDI-010976 shows dose-dependent inhibition of de novo lipogenesis in the liver in phase Ib trial
Read More
Selvita submits IND for SEL-24
Read More
FDA says additional phase III trial needed for approval of MCNA
Read More
Immunogen starts phase I trial of IMGN-779 in AML
Read More
IVA-337 demonstrates good safety and tolerability in phase IIa diabetes trial
Read More
Start of phase II trial evaluating GSK-3196165 in inflammatory hand osteoarthritis
Read More
Pieris licenses intellectual property related to Enumeral's anti-PD-1 antibody program
Read More
OSE Pharma and Effimune sign merger treaty to create OSE Immunotherapeutics
Read More
RedHill plans confirmatory phase III study for RHB-105
Read More
Novel antibacterial agent shows in vitro efficacy
Read More
Promathera acquires key assets of cell therapy firm Cytonet
Read More